Matches in SemOpenAlex for { <https://semopenalex.org/work/W2521989602> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2521989602 endingPage "459" @default.
- W2521989602 startingPage "459" @default.
- W2521989602 abstract "Soft tissue sarcomas (STS) include a spectrum of his-tologically and clinically different tumors. Patients are typically relatively young and the course of disease is characterized by early metastasis as well as limited response to chemotherapy. However, a few subtypes such as small round cell tumors (SRCTs) and rhabdomyosarcoma (except from pleomorphic), are considered chemotherapy-sensitive. In addition, reflecting successful translational research of recent years, gastrointestinal stromal tumor (GIST) and dermatofibrosarcoma protuberans have become model diseases for targeted oncological therapy. With a very limited number of active compounds at hand, treatment choices in metastatic STS with inkonsistent genomic alterations were easy to overview until only a few years ago. However, with novel therapeutic strategies such as the antiangiogenic approach and a multitude of novel compounds available both outside and within clinical studies, it may have become more difficult to keep track of currently available treatment options and their clinical safety and efficacy. Anthracyclines with or without ifosfamide are still considered standard of care in most STS-subtypes, especially in high-grade tumors. There is no evidence-based recommendation as to second-line treatment options. However, a number of established compounds, including dacarbazine/temozolomide, gemcitabine, taxanes, trofosfamide, DNA topoisomerase I inhibitors, DNA minor groove binders, and bendamustine, have shown activity. Recently, trabectedin, a DNA minor groove binder initially isolated from a sea sponge, has proven effective and received European approval for use in treatment-refractory STS. In addition, novel compounds such as bevacizumab, multityrosine kinase inhibitors, mTOR inhibitors, imatinib mesylate, and the thrombospondin agonist ABT 510 represent attractive partners for the above-mentioned cytostatic agents or may even be effective single agents in the clinically advanced setting. Novel combinations are being evaluated in clinical studies. In order to be successful, we may have to combine not only different compounds but also different targets beyond the proliferation machinery of sarcoma cells such as tumor angiogenesis, the tumor stromal compartment or tumor cell oncogene products." @default.
- W2521989602 created "2016-09-30" @default.
- W2521989602 creator A5050857187 @default.
- W2521989602 date "2010-07-01" @default.
- W2521989602 modified "2023-09-23" @default.
- W2521989602 title "6.O.01 POTENTIAL CHEMOTHERAPY APPROACHES FOR ADVANCED ADULT TYPE SOFT TISSUE SARCOMA" @default.
- W2521989602 hasPublicationYear "2010" @default.
- W2521989602 type Work @default.
- W2521989602 sameAs 2521989602 @default.
- W2521989602 citedByCount "0" @default.
- W2521989602 crossrefType "journal-article" @default.
- W2521989602 hasAuthorship W2521989602A5050857187 @default.
- W2521989602 hasConcept C121608353 @default.
- W2521989602 hasConcept C126322002 @default.
- W2521989602 hasConcept C142724271 @default.
- W2521989602 hasConcept C143998085 @default.
- W2521989602 hasConcept C2775930923 @default.
- W2521989602 hasConcept C2776694085 @default.
- W2521989602 hasConcept C2777389519 @default.
- W2521989602 hasConcept C2777506904 @default.
- W2521989602 hasConcept C2777583451 @default.
- W2521989602 hasConcept C2778119113 @default.
- W2521989602 hasConcept C2778256501 @default.
- W2521989602 hasConcept C2778464197 @default.
- W2521989602 hasConcept C2778629024 @default.
- W2521989602 hasConcept C2778729363 @default.
- W2521989602 hasConcept C2779490328 @default.
- W2521989602 hasConcept C2779744173 @default.
- W2521989602 hasConcept C2780259306 @default.
- W2521989602 hasConcept C2780752271 @default.
- W2521989602 hasConcept C2780844630 @default.
- W2521989602 hasConcept C2780964509 @default.
- W2521989602 hasConcept C3019892230 @default.
- W2521989602 hasConcept C502942594 @default.
- W2521989602 hasConcept C526805850 @default.
- W2521989602 hasConcept C530470458 @default.
- W2521989602 hasConcept C71924100 @default.
- W2521989602 hasConceptScore W2521989602C121608353 @default.
- W2521989602 hasConceptScore W2521989602C126322002 @default.
- W2521989602 hasConceptScore W2521989602C142724271 @default.
- W2521989602 hasConceptScore W2521989602C143998085 @default.
- W2521989602 hasConceptScore W2521989602C2775930923 @default.
- W2521989602 hasConceptScore W2521989602C2776694085 @default.
- W2521989602 hasConceptScore W2521989602C2777389519 @default.
- W2521989602 hasConceptScore W2521989602C2777506904 @default.
- W2521989602 hasConceptScore W2521989602C2777583451 @default.
- W2521989602 hasConceptScore W2521989602C2778119113 @default.
- W2521989602 hasConceptScore W2521989602C2778256501 @default.
- W2521989602 hasConceptScore W2521989602C2778464197 @default.
- W2521989602 hasConceptScore W2521989602C2778629024 @default.
- W2521989602 hasConceptScore W2521989602C2778729363 @default.
- W2521989602 hasConceptScore W2521989602C2779490328 @default.
- W2521989602 hasConceptScore W2521989602C2779744173 @default.
- W2521989602 hasConceptScore W2521989602C2780259306 @default.
- W2521989602 hasConceptScore W2521989602C2780752271 @default.
- W2521989602 hasConceptScore W2521989602C2780844630 @default.
- W2521989602 hasConceptScore W2521989602C2780964509 @default.
- W2521989602 hasConceptScore W2521989602C3019892230 @default.
- W2521989602 hasConceptScore W2521989602C502942594 @default.
- W2521989602 hasConceptScore W2521989602C526805850 @default.
- W2521989602 hasConceptScore W2521989602C530470458 @default.
- W2521989602 hasConceptScore W2521989602C71924100 @default.
- W2521989602 hasLocation W25219896021 @default.
- W2521989602 hasOpenAccess W2521989602 @default.
- W2521989602 hasPrimaryLocation W25219896021 @default.
- W2521989602 hasRelatedWork W1584984801 @default.
- W2521989602 hasRelatedWork W1989958318 @default.
- W2521989602 hasRelatedWork W2005270986 @default.
- W2521989602 hasRelatedWork W2008544080 @default.
- W2521989602 hasRelatedWork W2018133454 @default.
- W2521989602 hasRelatedWork W2071993782 @default.
- W2521989602 hasRelatedWork W2092435650 @default.
- W2521989602 hasRelatedWork W2093993947 @default.
- W2521989602 hasRelatedWork W2111997639 @default.
- W2521989602 hasRelatedWork W2171413733 @default.
- W2521989602 hasRelatedWork W2183002501 @default.
- W2521989602 hasRelatedWork W2290607182 @default.
- W2521989602 hasRelatedWork W2322233985 @default.
- W2521989602 hasRelatedWork W2404431718 @default.
- W2521989602 hasRelatedWork W2420944045 @default.
- W2521989602 hasRelatedWork W2802458193 @default.
- W2521989602 hasRelatedWork W2889291178 @default.
- W2521989602 hasRelatedWork W3030818972 @default.
- W2521989602 hasRelatedWork W56841874 @default.
- W2521989602 hasRelatedWork W77013686 @default.
- W2521989602 isParatext "false" @default.
- W2521989602 isRetracted "false" @default.
- W2521989602 magId "2521989602" @default.
- W2521989602 workType "article" @default.